| Description |
MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity[1].
|
| Related Catalog |
|
| In Vitro |
MTL-CEBPA does not significantly change total human CD45+ cells, and T lymphocytes (hCD4+ and hCD8+ T cell subsets) in PB. However, MTL-CEBPA treatment increases CD16+ granulocytes and CD14+ monocytes in peripheral blood (PB)[1].
|
| In Vivo |
MTL-CEBPA (iv; 3 mg/kg; on days 1, 3, and 5) demonstrates the specific activation of its target C/EBPα mRNA and its downstream gene p21 in naive hu-NSG mice[1]. MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model[1].
|
| References |
[1]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016. [2]. Reebye V, Huang KW, Lin V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216-3228. [3]. Combination therapies comprising C/EBPα-targeted short-activating RNA (saRNA). WO2022229644A1
|
